Boehringer Ingelheim & BioNTech launch high-stakes lung cancer combo trial

BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study

Exclusive | Bharat Biotech’s ROTAVAC halves severe diarrhoea hospitalisations in children, landmark Nature study confirms

Nature Medicine study delivers strongest real-world evidence yet for India’s indigenous rotavirus vaccine under UIP

Healthcare major QCIL signs solar power pacts with AMPIN and Radiance

Phase I to supply clean energy to five facilities, with long-term plans to power 19 hospitals through a 30 MW renewable network

AstraZeneca combo therapy shows breakthrough in liver cancer trial

The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival

Q2 2026 drug catalysts put Replimune, Arvinas and Boehringer in sharp focus: GlobalData

Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning

Middle East disruption hits thousands of global clinical trials, Phesi warns

The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment

Torqur taps Lonza to power late-stage push for skin cancer therapy

Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds

GSK seeks European nod for promising Hepatitis B therapy

Japan okays new long-acting eye drug

It promises fewer injections for vision loss patients

Bayer wins world-first nod in Japan for low-dose MRI contrast agent

Call it a major breakthrough for diagnostic imaging